RE:CZO: Key excerpts from Q4 2020 and Q1 2021ISAloser247 alias, let's start with the basics. You do not need to write your rambling comments in capital letters.
stockfy wrote:
CZO at a glance: Revenue YoY growth, profits, positive operating cash flow, positive free cash flow and a pristine cash-rich balance sheet without any debt problem in 2020.
Revenue YoY growth, profits and pristine balance sheet for CZO continued in Q1 2021.
Check also these key excerpts below, they are for serious investors.
These key excerpts are not day traders or penny flippers who have been posting shallow or inaccurate comments or even lies on this board almost every day.
This key excerpt is from the annual report that was out a few weeks ago:
“I strongly believe 2021 holds a lot of opportunity for Ceapro. Our focus remains on the health and safety of our associates during this COVID-19 pandemic crisis, followed by business continuity. Depending on the evolution of the COVID-19 pandemic, we expect Ceapro’s cosmeceuticals base business to continue to grow and provide positive operating cash flows to support the expansion to a new business model from a contract manufacturer to a biopharmaceutical development company involved in nutraceuticals and pharmaceuticals. Based on a very solid foundation, a highly competent team, a healthy balance sheet and a very strong technology and product portfolio with the potential to access key large markets, we have all the key components for success,” concluded Mr. Gagnon.
This key excerpt is from Q1 2021:
“While ensuring safety of our employees remained a top priority, we obtained solid results once again during the first quarter of this year and were successful at both growing our base business and also advancing some key research and development projects despite mandated stay-at-home orders in some Canadian provinces due to the ongoing COVID-19 pandemic. These results are a clear testament to the dedication and hard work of each of our employees during these challenging times and we are very proud of their commitment to support our customers heightened demand by delivering high quality products.
As we respond to the potential impacts and uncertainties of COVID-19 by taking the necessary steps to preserve our financial position, we continue to execute on our expansion to a new business model from a contract manufacturer/commodity company to a high-value life science/biopharmaceutical company. We remain dedicated to executing on our milestones ahead and should the Company be able to service its customers without disruption, we strongly believe the prospects for the Company remain very strong for the upcoming year,” concluded Mr. Gagnon.